Search Within

James Joseph Harding

  1. "Biostatistics Service"
Formats
  1. Meeting Abstract (32)
  2. Journal Article (31)
Groups
  1. Biostatistics Service (63)
  2. Department of Medicine (63)
  3. Epidemiology and Biostatistics (63)
  4. Gastrointestinal Oncology Service (63)
  5. Solid Tumor Oncology Division (63)
  6. Center for Pancreatic Cancer Research (56)

More Groups

People
  1. Ghassan Abou-Alfa (48)
  2. Marinela Capanu (36)
  3. Eileen O'Reilly (35)
  4. Joanne Chou (29)
  5. William Jarnagin (26)
  6. Imane El Dika (18)

More People

Years
  1. 2025 (4)
  2. 2024 (8)
  3. 2023 (5)
  4. 2022 (3)
  5. 2021 (4)
  6. 2020 (9)

More Years

Publications
  1. Journal of Clinical Oncology (28)
  2. Cancer (5)
  3. Clinical Cancer Research (4)
  4. The Oncologist (4)
  5. Annals of Surgical Oncology (3)
  6. JCO Precision Oncology (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (31)
  2. Wiley Blackwell (7)
  3. Oxford University Press (6)
  4. American Association for Cancer Research (4)
  5. Springer (4)
  6. Elsevier Science, Inc. (2)

More Publishers

Results (63)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II trial of sorafenib plus doxorubicin (SD) in patients (Pts) with advanced hepatocellular carcinoma (HCC) after progression of disease (PD) on sorafenib (S)
    Meeting Abstract

    El Dika, I. H.; Capanu, M.; Chou, J. F.; Harding, J. J.; Hrabovsky, A. D.; Do, R. K. G.; Shia, J.; Germino, J.; O'Reilly, E. M.; Abou-Alfa, G. K.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: Potential targets for intervention
    Journal Article

    Lowery, M. A.; Ptashkin, R.; Jordan, E.; Berger, M. F.; Zehir, A.; Capanu, M.; Kemeny, N. E.; O'Reilly, E. M.; El-Dika, I.; Jarnagin, W. R.; more...
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • Frequency, morbidity, and mortality of bone metastases in advanced hepatocellular carcinoma
    Journal Article

    Harding, J. J.; Abu-Zeinah, G.; Chou, J. F.; Owen, D. H.; Ly, M.; Lowery, M. A.; Capanu, M.; Do, R.; Kemeny, N. E.; O'Reilly, E. M.; more...
    Journal of the National Comprehensive Cancer Network (2018)

    Fulltext@MSK | Save
  • PTEN loss-of-function alterations are associated with intrinsic resistance to BRAF inhibitors in metastatic melanoma
    Journal Article

    Catalanotti, F.; Cheng, D. T.; Shoushtari, A. N.; Johnson, D. B.; Panageas, K. S.; Momtaz, P.; Higham, C.; Won, H. H.; Harding, J. J.; Merghoub, T.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • A phase I/II trial of MEK162 in combination with gemcitabine (G) and cisplatin (C) for patients (pts) with untreated advanced biliary cancer (ABC)
    Meeting Abstract

    Lowery, M. A.; O'Reilly, E. M.; Harding, J. J.; Yu, K. H.; Cercek, A.; Hollywood, E.; Salehi, E.; Margona, E.; Bradley, M.; Witter, T.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase IB trial of ADI-PEG 20 (A) plus nab-paclitaxel (nab-P) and gemcitabine (gem) in patients with advanced pancreatic cancer (PC)
    Meeting Abstract

    Lowery, M. A.; Harding, J. J.; Yu, K. H.; Kelsen, D. P.; Bomalaski, J. S.; Glassman, D. C.; Covington, C. M.; Brenner, R.; Hollywood, E.; Barba, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Molecular landscape of fibrolamellar carcinoma (FLC): Beyond the DNAJB1-PRKACA chimera
    Meeting Abstract

    El Dika, I. H.; Capanu, M.; Berger, M. F.; Arcila, M. E.; Benayed, R.; Harding, J. J.; Rusek, M.; Valentino, E.; O'Reilly, E. M.; Saltz, L.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A situation where hepatocellular carcinoma (HCC) may be more common in women than men: Clinical and genetic patterns of non risk-factored HCC
    Meeting Abstract

    El Dika, I. H.; Harding, J. J.; Capanu, M.; Berger, M. F.; Rebibo, D.; Rusek, M.; Chou, J. F.; O'Reilly, E. M.; Saltz, L.; Abou-Alfa, G. K.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
    Journal Article

    Smyth, L. M.; Monson, K. R.; Jhaveri, K.; Drilon, A.; Li, B. T.; Abida, W.; Iyer, G.; Gerecitano, J. F.; Gounder, M.; Harding, J. J.; more...
    Investigational New Drugs (2017)

    Fulltext@MSK | Save
  • A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma
    Journal Article

    Lowery, M. A.; Yu, K. H.; Kelsen, D. P.; Harding, J. J.; Bomalaski, J. S.; Glassman, D. C.; Covington, C. M.; Brenner, R.; Hollywood, E.; Barba, A.; more...
    Cancer (2017)

    Fulltext@MSK | Save